Literature DB >> 8018303

Drug-induced hair loss and hair growth. Incidence, management and avoidance.

A Tosi1, C Misciali, B M Piraccini, A M Peluso, F Bardazzi.   

Abstract

A large number of drugs may interfere with the hair cycle and produce hair loss. Drugs may affect anagen follicles through 2 main different modalities: (i) by inducing an abrupt cessation of mitotic activity in rapidly dividing hair matrix cells (anagen effluvium) or (ii) by precipitating the follicles into premature rest (telogen effluvium). In anagen effluvium, hair loss usually occurs within days to weeks of drug administration, whereas in telogen effluvium, hair loss becomes evident 2 to 4 months after starting treatment. Anagen effluvium is a prominent adverse effect of antineoplastic agents, which cause acute damage of rapidly dividing hair matrix cells. Telogen effluvium may be a consequence of a large number of drugs including anticoagulants, retinol (vitamin A) and its derivatives, interferons and antihyperlipidaemic drugs. Drug-induced hair loss is usually reversible after interruption of treatment. The prevalence and severity of alopecia depend on the drug as well as on individual predisposition. Some drugs produce hair loss in most patients receiving appropriate dosages while other drugs are only occasionally responsible for hair abnormalities. Both hirsutism and hypertrichosis may be associated with drug administration. Drugs most commonly responsible for the development of hirsutism include testosterone, danazol, corticotrophin (ACTH), metyrapone, anabolic steroids and glucocorticoids. Hypertrichosis is a common adverse effect of cyclosporin, minoxidil and diazoxide.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8018303     DOI: 10.2165/00002018-199410040-00005

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  37 in total

1.  Pathologic dynamics of human hair loss. I. Telogen effuvium.

Authors:  A M KLIGMAN
Journal:  Arch Dermatol       Date:  1961-02

Review 2.  [Cutaneous side effects of antitumor chemotherapy].

Authors:  M Delaunay
Journal:  Ann Dermatol Venereol       Date:  1989       Impact factor: 0.777

3.  Erythropoietin and abnormal hair growth in hemodialysis patients.

Authors:  M J Kleiner; D Serur; M Knowles; G Herskovits; A Sollazzo
Journal:  Am J Kidney Dis       Date:  1991-11       Impact factor: 8.860

Review 4.  Etretinate therapy.

Authors:  C N Ellis; J J Voorhees
Journal:  J Am Acad Dermatol       Date:  1987-02       Impact factor: 11.527

5.  Transverse microscopic anatomy of the human scalp. A basis for a morphometric approach to disorders of the hair follicle.

Authors:  J T Headington
Journal:  Arch Dermatol       Date:  1984-04

Review 6.  Topically applied minoxidil in baldness.

Authors:  E Novak; T J Franz; J T Headington; R C Wester
Journal:  Int J Dermatol       Date:  1985-03       Impact factor: 2.736

7.  Hair loss following lithium therapy.

Authors:  A Orwin
Journal:  Br J Dermatol       Date:  1983-04       Impact factor: 9.302

8.  Thallium poisoning: a dermatological perspective.

Authors:  T Heyl; R J Barlow
Journal:  Br J Dermatol       Date:  1989-12       Impact factor: 9.302

9.  Side effects of long-term treatment with human leukocyte interferon.

Authors:  S Ingimarsson; K Cantell; H Strander
Journal:  J Infect Dis       Date:  1979-10       Impact factor: 5.226

10.  Report of a patient with lithium-related alopecia and psoriasis.

Authors:  A M Ghadirian; M Lalinec-Michaud
Journal:  J Clin Psychiatry       Date:  1986-04       Impact factor: 4.384

View more
  17 in total

1.  Treatment for chemotherapy-induced alopecia in mice using parathyroid hormone agonists and antagonists linked to a collagen binding domain.

Authors:  Ranjitha Katikaneni; Tulasi Ponnapakkam; Hirofumi Suda; Shigeru Miyata; Joshua Sakon; Osamu Matsushita; Robert C Gensure
Journal:  Int J Cancer       Date:  2012-01-24       Impact factor: 7.396

2.  Leflunomide: an unlikely trigger and mechanistically a beneficial drug for alopecia areata.

Authors:  Kabir Sardana; Aastha Gupta; Pulin Kumar Gupta
Journal:  Clin Rheumatol       Date:  2019-07-23       Impact factor: 2.980

3.  Alopecia in survivors of critical illness.

Authors:  Ceri E Battle; Karen James; Paul Temblett
Journal:  J Intensive Care Soc       Date:  2016-07-25

4.  Acute and 30-day oral toxicity studies of a novel coccidiostat - ethanamizuril.

Authors:  Wenlong Xiao; Xiaoyang Wang; Chunmei Wang; Mi Wang; Chenzhong Fei; Lifang Zhang; Feiqun Xue; Guoyong Wang; Keyu Zhang
Journal:  Toxicol Res (Camb)       Date:  2019-07-04       Impact factor: 3.524

Review 5.  Hair disorders in patients with cancer.

Authors:  Azael Freites-Martinez; Jerry Shapiro; Shari Goldfarb; Julie Nangia; Joaquin J Jimenez; Ralf Paus; Mario E Lacouture
Journal:  J Am Acad Dermatol       Date:  2018-04-14       Impact factor: 11.527

6.  Alopecia in association with lamotrigine use: an analysis of individual case safety reports in a global database.

Authors:  Maria Tengstrand; Kristina Star; Eugène P van Puijenbroek; Richard Hill
Journal:  Drug Saf       Date:  2010-08-01       Impact factor: 5.606

Review 7.  Drug-induced skin, nail and hair disorders.

Authors:  Laurence Valeyrie-Allanore; Bruno Sassolas; Jean-Claude Roujeau
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

Review 8.  TREATMENT OF CUSHING'S SYNDROME : WHAT PLACE FOR MEDICAL TREATMENT?

Authors:  O Chabre; J Cristante
Journal:  Acta Endocrinol (Buchar)       Date:  2019 Apr-Jun       Impact factor: 0.877

9.  Isoniazid-induced alopecia.

Authors:  K B Gupta; V Kumar; S Vishvkarma; R Shandily
Journal:  Lung India       Date:  2011-01

10.  Serum drug level-related sodium valproate-induced hair loss.

Authors:  Suresh K Ramakrishnappa; Mahesh N Belhekar
Journal:  Indian J Pharmacol       Date:  2013 Mar-Apr       Impact factor: 1.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.